• Contact
Augurex
  • Solutions
    • Solution Portfolio
    • Rheumatoid Arthritis
    • Axial Spondyloarthritis
    • Find a Test
  • Science
  • About
    • Company
    • Leadership
  • News
  • Careers
Select Page
RheumNow Highlights Anti-14-3-3eta Multiplex Data in ACR 2025 Coverage: Biomarker Discovery in axSpA

RheumNow Highlights Anti-14-3-3eta Multiplex Data in ACR 2025 Coverage: Biomarker Discovery in axSpA

by George Ciuciureanu | Oct 31, 2025 | Health, News

Vancouver, Canada – October 31, 2025 – Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced that RheumNow, a leading rheumatology news platform, has featured Augurex’s latest ACR Convergence 2025 data on the Anti-14-3-3eta...
RheumNow’s ACR 2025 coverage highlights Augurex’s data on Anti-14-3-3eta Multiplex Immunoassay Test

RheumNow’s ACR 2025 coverage highlights Augurex’s data on Anti-14-3-3eta Multiplex Immunoassay Test

by George Ciuciureanu | Oct 28, 2025 | Health, News

Vancouver, Canada – 28 October, 2025 – Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced that RheumNow, a leading rheumatology news platform, has featured Augurex’s latest ACR Convergence 2025 data on the Anti-14-3-3eta...
Augurex Life Sciences Granted FDA Breakthrough Designation for SPINEstat®, its First-in-Class Diagnostic Test for Axial Spondyloarthritis

Augurex Life Sciences Granted FDA Breakthrough Designation for SPINEstat®, its First-in-Class Diagnostic Test for Axial Spondyloarthritis

by George Ciuciureanu | Oct 28, 2025 | Health, News

The U.S. FDA has granted Breakthrough Device Designation to SPINEstat® (14-3-3eta Autoantibody Multiplex Immunoassay Test), recognizing its potential to address a significant unmet need in the diagnosis of patients with axial spondyloarthritis (axSpA). SPINEstat®,...
AiArthritis has launched a new patient education feature focused on the 14-3-3eta blood test in rheumatoid arthritis (RA)

AiArthritis has launched a new patient education feature focused on the 14-3-3eta blood test in rheumatoid arthritis (RA)

by George Ciuciureanu | Oct 22, 2025 | Health, News

Vancouver, Canada – October 22, 2025 — Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced that AiArthritis has launched a new patient education feature focused on the 14-3-3eta blood test in rheumatoid arthritis (RA)....
Augurex to Exhibit and Present New Data on Anti-14-3-3eta Multiplex in Axial Spondyloarthritis at ACR Convergence 2025

Augurex to Exhibit and Present New Data on Anti-14-3-3eta Multiplex in Axial Spondyloarthritis at ACR Convergence 2025

by George Ciuciureanu | Oct 17, 2025 | Events, Health

Vancouver, Canada – October 17, 2025 – Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced that it will be exhibiting at Booth 919 and presenting new data at the American College of Rheumatology (ACR) Convergence 2025, taking...
Page 2 of 7«12345…»Last »
©2024 Augurex Life Sciences. All Rights Reserved. Website by Vanooms Media Inc.